Adage Capital Partners Gp, L.L.C. Prometheus Biosciences, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$103.46 - $126.29 $70.5 Million - $86 Million	-681,133 Reduced 61.82%	420,706 $45.2 Million
Q4 2022 Feb 14, 2023	SELL	$36.06 - $117.21 $2.28 Million - $7.4 Million	-63,161 Reduced 5.42%	1,101,839 $121 Million
Q3 2022 Nov 14, 2022	BUY	$28.17 - $59.01 $32.8 Million - $68.7 Million	1,165,000 New	1,165,000 $68.7 Million
Q4 2021 Feb 14, 2022	SELL	$22.28 - $39.54 $7.74 Million - $13.7 Million	-347,315 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$20.89 - $26.96 $578,339 - $746,387	-27,685 Reduced 7.38%	347,315 $8.24 Million
Q2 2021 Aug 16, 2021	SELL	$16.8 - $29.65 $1.68 Million - $2.97 Million	-100,000 Reduced 21.05%	375,000 $9.21 Million
Q1 2021 May 17, 2021	BUY	$16.51 - $25.29 $7.84 Million - $12 Million	475,000 New	475,000 $8.67 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.